AI Article Synopsis
- The study analyzed the treatment outcomes and survival rates of patients with recurrent versus de novo stage IV advanced cancers, specifically breast, lung, and colorectal cancers, using data from 4,510 patients.
- The findings revealed that patients with recurrent lung cancer had a longer survival than those with de novo lung cancer, while there was no significant survival difference for colorectal cancer and shorter survival for recurrent breast cancer.
- The research highlighted that de novo cases often received more chemotherapy and radiation therapy, suggesting that understanding these differences could improve prognostic estimates and aid in designing clinical trials.
Article Abstract
The treatments provided to and survival of patients with recurrent vs de novo stage IV advanced breast, lung, and colorectal cancer may differ but have not been well studied. Using population-based data from the Cancer Research Network for 4510 patients with advanced breast, lung, or colorectal cancer, we matched recurrent/de novo patients on demographic factors. We found longer survival for recurrent vs de novo lung cancer (182 matched pairs); no significant difference for colorectal cancer (332 matched pairs); and shorter survival for recurrent vs de novo breast cancer (219 matched pairs). Compared with recurrent cases, chemotherapy use and radiation therapy use were more common among de novo cases. Differences in treatment and survival between recurrent and de novo advanced cancer patients could inform prognostic estimates and clinical trial design.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024888 | PMC |
| http://dx.doi.org/10.1093/jncics/pky024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!